Publication Topic

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, March 6-10, 2011, Washington, D.C.

Proctor D, Meek B. Using mode of action data to guide quantitative cancer risk assessment: A case study of hexavalent chromium in drinking water. Presented at Society of Toxicology 50th Annual Meeting, March 6-10, Washington, DC, March 2011.

Alexander DD, Wagner ME. 2010. Benzene exposure and non-Hodgkin lymphoma: A meta-analysis of epidemiologic studies. J Occup Environ Med 52(2):169–189; doi: 10.1097/JOM.0b013e3181cc9cf0.

Kelsh MA, Morimoto L, Lau E. Cancer mortality and oil production in the Amazon region of Ecuador. 2009. Int Arch Occup Environ Health 82(3): 381–395.

Thompson CM, Grafstrom RC. 2009. Commentary: Mechanistic considerations for associations between formaldehyde exposure and nasopharyngeal carcinoma. Environ Health 8:53; doi: 10.1186/1476-069X-8-53.

Elespuru RK, Agarwal R, Atrakchi A, Bigger CAH, Heflich RH, Jagannath D, Levy DD…Robison TW, et al. 2009. Current and future application of genetic toxicity assays: The role and value of in vitro mammalian assays. Toxicol Sci 109(2):172-179; doi: 10.1093/toxsci/kfp067.

Kelsh MA, Alexander DD, Kalmes RM, Buffler PA. 2008. Personal use of hair dyes and risk of bladder cancer: A meta-analysis of epidemiologic data. Cancer Causes Control 19(6):549–558.

Mink PJ, Alexander DD, Barraj LM, Kelsh MA, Tsuji JS. 2008. Low-level arsenic exposure in drinking water and bladder cancer: A review and meta-analysis. Regul Toxicol Pharmacol 52(3):299–310.

Subramaniam RP, Chen C, Crump KS, Devoney D, Fox JF, Portier CJ, Schlosser PM, Thompson CM, White P. 2008. Uncertainties in biologically-based modeling of formaldehyde-induced respiratory cancer risk: Identification of key issues. Risk Analysis 28(4):907–923; doi: 10.1111/j.1539-6924.2008.01083.x.

Proctor DM, Gatto NM, Hong SJ, Allamneni KP. 2007. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment. Toxicol Sci 98(2):313–326; doi: 10.1093/toxsci/kfm075.

Lea IA, Jackson MA, Li X, Bailey S, Peddada SD, Dunnick JK. 2007. Genetic pathways and mutation profiles of human cancers: Site- and exposure-specific patterns. Carcinogenesis 28(9):1851–1858; doi: 10.1093/carcin/bgm176.

Teta MJ, Lau E, Sceurman BK, Wagner ME. 2007. Therapeutic radiation for lymphoma: Risk of malignant mesothelioma. Cancer 109(7):1432–1438; doi: 10.1002/cncr.22526.

David RM, Clewell HJ, Gentry PR, Covington TR, Morgott DA, Marino DJ. 2006. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations. Regul Toxicol Pharmacol 45(1):55–65.

Marino DJ, Clewell HJ, Gentry PR, Covington TR, Hack CE, David RM, Morgott DA. 2006. Revised assessment of cancer risk to dichloromethane: Part I Bayesian PBPK and dose-response modeling in mice. Regul Toxicol Pharmacol 45(1):44–54.

Degregorio MW, Dingley KH, Wurz GT, Ubick E, Turteltaub KW. 2006. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. Cancer Chemother Pharmacol 57(3):335-342; doi: 10.1007/s00280-005-0060-1. PMID: 16047147.

Malfatti MA, Dingley KH, Nowell-Kadlubar S, Ubick EA, Mulakken N, Nelson D, Lang NP, et al. 2006. The urinary metabolite profile of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine is predictive of colon DNA adducts after a low-dose exposure in humans. Cancer Res 66(21):10541–10547; doi: 10.1158/0008-5472.CAN-06-1573. PMID: 17079477.

Jackson MA, Lea I, Rashid A, Peddada SD, Dunnick JK. 2006. Genetic alterations in cancer knowledge system: Analysis of gene mutations in mouse and human liver and lung tumors. Toxicol Sci 90(2):400–418; doi: 10.1093/toxsci/kfj101.

Ebeler SE, Dingley KH, Ubick E, Abel S, Mitchell AE, Burns SA, et al. 2005. Animal models and analytical approaches for understanding the relationships between wine and cancer. Drugs Exp Clin Res 31(1):19–27. PMID: 15921026.

Warren DA, Kerger BD, Britt JK, James RC. 2004. Development of an oral cancer slope factor for Aroclor 1268. Regul Toxicol Pharmacol 40(1):42-53; doi: 10.1016/j.yrtph.2004.04.005.

Crump C, Crump K, Hack E, Luippold R, Mundt K, Liebig EW, Panko JM, Paustenbach DJ, Proctor DM. 2003. Dose-response and risk assessment of airborne hexavalent chromium and lung cancer mortality. Risk Anal 23(6):1147–1163; doi: 10.1111/j.0272-4332.2003.00388.x.